Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06020807 · ClinicalTrials.gov registry record
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
A clinical trial, sponsored by Nucleix.
- Completed
- Registry status
- 168
- Enrollment target
NCT06020807: Completed study, sponsored by Nucleix.
NCT06020807 is a clinical trial that has completed, run by Nucleix. The registered enrollment target is 168 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06020807 has completed, sponsored by Nucleix.
- COMPLETED
- Registry status
- 168 participants
- Enrollment target
Study Summary
This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.
Primary Outcome
The primary endpoint of the study is the specificity of the Bladder EpiCheck Test in healthy population.
Interventions
- DIAGNOSTIC_TEST Bladder EpiCheck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2020-01-08 |
What the finished NCT06020807 record still lists
NCT06020807 is an observational study that tracks outcomes without assigning an intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Bladder EpiCheck is the first listed.
NCT06020807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06020807 about?
NCT06020807 is a clinical study titled "Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer". This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.
What is the current status of trial NCT06020807?
This trial is currently completed. The enrollment target is 168 participants. The study started on 2019-09-05. Estimated completion is 2020-01-08.
What interventions are being tested in trial NCT06020807?
The interventions under investigation include: Bladder EpiCheck (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06020807?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI